China’s national regulator has approved Sinovac Biotech’s COVID-19 vaccine for use by the general public.
This is the second vaccine approved by China’s National Medical Products Administration (NMPA).
Both of the vaccines, along with another experimental vaccine from Sinopharm, have been used in China’s vaccination programme.
More than 31 million doses have been administered, mainly targeting groups at higher infection risks, while a fourth experimental vaccine from CanSino Biologics has been given to military personnel.
Read the full article.